HK Stock Market Move | HBM HOLDINGS-B(02142) rose by more than 4%, announcing the release of the first comprehensive human-derived HCAb generation model to accelerate the implementation of the next generation therapies.

HBM HOLDINGS-B (02142) rose more than 4%, as of the time of writing, it rose 3.29% to 13.49 Hong Kong dollars, with a turnover of 52.54 million Hong Kong dollars. On the news front, according to the official WeChat account of Hebao Pharmaceuticals, on October 28th, the "Zhao Yao Hebao Hui Chuang Xingchen" global R&D day event was successfully held in Shanghai, China. At the event, Hebao Pharmaceuticals officially released its first fully human AI HCAb model driven by the Hu-mAtrIx artificial intelligence platform - a full human recombined antibodies (HCAb) generation and screening model. This model is based on Hebao Pharmaceuticals' proprietary Harbour Mice platform data, integrating a fine-tuned large language model (LLM) for sequence generation, along with high-precision AI classification and drug-like prediction models. Unlike traditional screening methods, this platform achieves a closed-loop process of AI design, intelligent screening, and wet laboratory verification. It is expected that based on this system, the AI HCAb model will accelerate the application of full human HCAbs in the field of next-generation therapies - including multi-specific antibodies, XDC, in vivo CAR-T, and inhaled or orally administered large molecule drugs - helping to reshape the landscape of biopharmaceutical research and development. Leveraging AI capabilities and the foundation of HCAb technology, Hebao Pharmaceuticals is accelerating the implementation of next-generation innovative therapies, and exploring unmet clinical needs through a data-driven predictive process.